(-)-Epigallocatechin Gallate (Synonyms: EGCG; Epigallocatechol Gallate)

目录号: HY-13653 纯度: 99.87%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

(-)-Epigallocatechin Gallate sulfate (EGCG) 是绿茶中的一种主要多酚，可抑制细胞增殖并诱导细胞凋亡。 (-)-Epigallocatechin Gallate sulfate 可抑制谷氨酸脱氢酶 1/2 (GDH1/2, GLUD1/2) 的活性。(-)-Epigallocatechin Gallate sulfate 对结直肠癌、髓性白血病、甲状腺癌等多种癌症具有有效的抗癌、抗氧化和抗炎特性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(-)-Epigallocatechin Gallate Chemical Structure

CAS No. : 989-51-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
50 mg	￥369	In-stock
100 mg	￥550	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of (-)-Epigallocatechin Gallate:

(-)-Epigallocatechin In-stock
(-)-Gallocatechin gallate In-stock
(-)-Epigallocatechin Gallate (Standard) In-stock
(+/-)-Epigallocatechin Gallate-¹³C₃ 询价

MCE 顾客使用本产品发表的 34 篇科研文献

: (-)-Epigallocatechin Gallate purchased from MCE. Usage Cited in: Oncol Lett. 2017 Nov;14(5):6314-6320. [Abstract]; Effects of EGCG on the levels of SHP 1 and p p38α protein expres¬sion in NB4 cells.

(-)-Epigallocatechin Gallate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma^[1]^[2]^[3]^[4].

IC₅₀ & Target^[1]

EGFR

HER2

HER3

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	112 μM Compound: EGCG	Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry	[PMID: 23628332]
A-431	EC₅₀	266 μM Compound: 1, EGCG	Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A-431	EC₅₀	38 μM Compound: 1, EGCG	Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A549	IC₅₀	185 μM Compound: EGCG	Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
A549	IC₅₀	29 μM Compound: EGCG	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
BXPC-3	IC₅₀	33 μM Compound: EGCG	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
CHO	IC₅₀	271 μM Compound: EGCG	Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay	[PMID: 23327877]
CHO	IC₅₀	3.2 μM Compound: EGCG	Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay	[PMID: 23327877]
CHO	IC₅₀	7.7 μM Compound: EGCG	Cytotoxicity against CHO cells expressing OATP1B11b after 48 hrs by fluorescence based CellTiter-Glo assay Cytotoxicity against CHO cells expressing OATP1B11b after 48 hrs by fluorescence based CellTiter-Glo assay	[PMID: 23327877]
COLO 201	IC₅₀	38 μM Compound: EGCG	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HCT-116	IC₅₀	161 μM Compound: EGCG	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 12880319]
HCT-116	IC₅₀	5 μM Compound: 54	Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay	[PMID: 33445154]
HeLa	IC₅₀	1.08 μM Compound: 4, EGCG	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol	[PMID: 22413845]
HeLa	IC₅₀	1.18 μM Compound: 4, EGCG	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol	[PMID: 22413845]
HL-60	IC₅₀	9.4 μM Compound: EGCG	Antiproliferative activity against human HL60 cells after 3 days Antiproliferative activity against human HL60 cells after 3 days	[PMID: 18693020]
HSC-T6	IC₅₀	31.6 μM Compound: (-)-EGCG	Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay	[PMID: 28257196]
HSC-T6	IC₅₀	9.9 μM Compound: EGCG	Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay	[PMID: 18052323]
HSC-T6	IC₅₀	9.9 μM Compound: EGCG	Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay	[PMID: 21504848]
HT-22	IC₅₀	23.8 μM Compound: 42; EGCG	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	60 μM Compound: EGCG	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Huh-7	IC₅₀	20 μM Compound: 5, EGCG	Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay	[PMID: 25103601]
Jurkat	IC₅₀	1 μM Compound: (-)-EGCG	Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis	[PMID: 30776692]
Jurkat	IC₅₀	18 μM Compound: (-)-EGCG	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro	[PMID: 30776692]
L1210	IC₅₀	690 μM Compound: EGCG	Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay	[PMID: 18951028]
L929	IC₅₀	82.3 μM Compound: EGCG	Cytotoxicity against mouse L929 cells after 3 days by MTS assay Cytotoxicity against mouse L929 cells after 3 days by MTS assay	[PMID: 25985195]
LN-229	IC₅₀	15 μM Compound: EGCG	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LX-2	CC₅₀	> 100 μM Compound: EGCG	Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay	[PMID: 34610571]
MDA-MB-231	IC₅₀	76.1 μM Compound: EGCG	Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay	[PMID: 25453798]
MDA-MB-231	IC₅₀	83 μM Compound: EGCG	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDCK	CC₅₀	> 200 μM Compound: EGCG	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31954881]
MDCK	CC₅₀	275 μM Compound: 1, EGCG	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18547804]
MDCK	CC₅₀	275.4 μM Compound: 56; EGCG	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28118010]
MDCK	IC₅₀	41.25 μM Compound: 1, EGCG	Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay	[PMID: 17420124]
MDCK	ED₅₀	8.3 μM Compound: 3, EGCG	Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR	[PMID: 22115591]
NCI-H1299	IC₅₀	> 80 μM Compound: EGCG	Antiproliferative activity in human NCI-H1299 cells after 72 hrs Antiproliferative activity in human NCI-H1299 cells after 72 hrs	[PMID: 29530347]
NCI-H1299	IC₅₀	20.6 μM Compound: EGCG	Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
NCI-H1650	IC₅₀	24.8 μM Compound: EGCG	Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
NCI-H1703	IC₅₀	17.1 μM Compound: EGCG	Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
NCI-H460	IC₅₀	18 μM Compound: EGCG	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PANC-1	IC₅₀	62 μM Compound: EGCG	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PC-9	IC₅₀	77.4 μM Compound: EGCG	Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
Peritoneal macrophage cell	IC₅₀	436.3 μM Compound: 1, EGCG	Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay	[PMID: 24106750]
RAW264.7	IC₅₀	29.8 μM Compound: EGCG	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days	[PMID: 21456521]
Sf9	IC₅₀	0.5 μM Compound: 9, EGCG	Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil	[PMID: 25406944]
SK-BR-3	EC₅₀	100 μM Compound: 1, EGCG	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-BR-3	IC₅₀	149 μM Compound: 4, EGCG	Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 22559865]
SK-BR-3	EC₅₀	195 μM Compound: 1, EGCG	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-MEL-2	IC₅₀	31 μM Compound: EGCG	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SW480	IC₅₀	195 μM Compound: EGCG	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 12880319]
T47D	IC₅₀	57 μM Compound: EGCG	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T98G	IC₅₀	166 μM Compound: EGCG	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay	[PMID: 26631318]
U-87MG ATCC	IC₅₀	18 μM Compound: EGCG	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]

体外研究
(In Vitro)

(-)-Epigallocatechin Gallate (EGCG，10-60 μM) 以剂量依赖性方式抑制 FB-2 和 WRO 细胞的生长^[1]。
(-)-Epigallocatechin Gallate (10-60 μM，0-24 h) 减少细胞周期蛋白 D1 和 AKT 和 ERK1/2 的磷酸化，并增加 p21 和 p53 的表达^[1]。
(-)-Epigallocatechin Gallate (10-60 μM，12 小时) 降低细胞运动和迁移^[1]。
(-)-Epigallocatechin Gallate (0 -20 μM，约 0-20 分钟) 抑制 GLUD1/2 和 IDH1 活性呈浓度和时间依赖性 (生化测定)^[2]。
(-)- Epigallocatechin Gallate (0-35 μg/mL，24-72 小时) 抑制结直肠癌细胞 (LoVo、SW480、HT-29、HCT-8细胞) 的增殖，增加细胞凋亡，阻滞细胞在G0/G1期^[3]。
(-)-Epigallocatechin Gallate (30 μM，3-24 h) 抑制 LPS 诱导的成骨细胞中 COX-2 和 mPGES-1 mRNA 的表达以及前列腺素 E2 的产生^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	FB-2 and WRO cells (serum-starved for 48h)
Concentration:	10, 40, 60 μM.
Incubation Time:	4 days
Result:	Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).

Western Blot Analysis^[1]

Cell Line:	FB-2 cells
Concentration:	10, 40, 60 μM.
Incubation Time:	24 h
Result:	Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2. Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin.

Cell Migration Assay ^[1]

Cell Line:	FB-2 and WRO cells (serum-starved for 48h)
Concentration:	10, 40, 60 μM.
Incubation Time:	12 h
Result:	Reduced migration activity in FB-2 and WRO cells.

RT-PCR^[4]

Cell Line:	Mouse primary osteoblasts (1 ng/ml LPS-treated)
Concentration:	30 μM
Incubation Time:	3, 6, 12, 24 h
Result:	Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.

体内研究
(In Vivo)

(-)- Epigallocatechin Gallate (灌胃给药，5 -20 mg/kg，每天一次，持续 14 天，原位移植模型) 减少肿瘤生长^[3]。
(-)- Epigallocatechin Gallate (注射入小鼠下牙龈，单剂量 0.5 mg/小鼠，实验性牙周炎模型) 降低抑制 LPS 诱导的骨密度 (BMD) 损失^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Orthotopic transplant BALB/c nude mice model^[3]
Dosage:	5, 10, and 20 mg/kg, once daily for 14 days.
Administration:	Intragastrical administration.
Result:	Inhibited tumors growth with no liver or lung metastases.

Animal Model:	Model of experimental periodontitis, LPS (25 μg/mouse)^[4]
Dosage:	0.5 mg/mouse, a single dose.
Administration:	Injected into the mouse lower gingiva
Result:	Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.

Clinical Trial

分子量

458.37

Formula

C₂₂H₁₈O₁₁

CAS 号

989-51-5

性状

固体

颜色

Off-white to pink

中文名称

(-)-表没食子儿茶素没食子酸酯

结构分类

初始来源

内源性代谢物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 30 mg/mL (65.45 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 20 mg/mL (43.63 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1816 mL	10.9082 mL	21.8164 mL
5 mM	0.4363 mL	2.1816 mL	4.3633 mL
10 mM	0.2182 mL	1.0908 mL	2.1816 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.54 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.54 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.54 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 9.09 mg/mL (19.83 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.87%

选择批次：

Data Sheet (657 KB) SDS (394 KB)

COA (201 KB) LCMS (266 KB)

产品使用指南 (1538 KB)

参考文献

[1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1. [Content Brief]

[2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4. [Content Brief]

[3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53. [Content Brief]

[4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7. [Content Brief]

(-)-Epigallocatechin Gallate 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.1816 mL	10.9082 mL	21.8164 mL	54.5411 mL
	5 mM	0.4363 mL	2.1816 mL	4.3633 mL	10.9082 mL
	10 mM	0.2182 mL	1.0908 mL	2.1816 mL	5.4541 mL
	15 mM	0.1454 mL	0.7272 mL	1.4544 mL	3.6361 mL
	20 mM	0.1091 mL	0.5454 mL	1.0908 mL	2.7271 mL
	25 mM	0.0873 mL	0.4363 mL	0.8727 mL	2.1816 mL
	30 mM	0.0727 mL	0.3636 mL	0.7272 mL	1.8180 mL
	40 mM	0.0545 mL	0.2727 mL	0.5454 mL	1.3635 mL
DMSO	50 mM	0.0436 mL	0.2182 mL	0.4363 mL	1.0908 mL
DMSO	60 mM	0.0364 mL	0.1818 mL	0.3636 mL	0.9090 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(-)-Epigallocatechin Gallate989-51-5EGCG Epigallocatechol Gallate(-)-表没食子儿茶素没食子酸酯Endogenous MetaboliteApoptosisThyroid cancerFB-2 cellsLPS-induced bone resorptioncolorectal cancercell proliferation.Inhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

(-)-Epigallocatechin Gallate (Synonyms: EGCG; Epigallocatechol Gallate)

Customer Review

Other Forms of (-)-Epigallocatechin Gallate:

MCE 顾客使用本产品发表的 34 篇科研文献

(-)-Epigallocatechin Gallate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

(-)-Epigallocatechin Gallate 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

(-)-Epigallocatechin Gallate (Synonyms: EGCG; Epigallocatechol Gallate)

Customer Review

Other Forms of (-)-Epigallocatechin Gallate:

(-)-Epigallocatechin Gallate 相关抗体

MCE 顾客使用本产品发表的 34 篇科研文献

(-)-Epigallocatechin Gallate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

(-)-Epigallocatechin Gallate 相关抗体:

摩尔计算器

稀释计算器

(-)-Epigallocatechin Gallate 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z